Basic information Safety Supplier Related

5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL

Basic information Safety Supplier Related

5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Basic information

Product Name:
5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL
Synonyms:
  • 5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL
  • O-1821
  • O-1821 (CRM)
  • 1,3-Benzenediol, 5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-
CAS:
35482-50-9
MF:
C17H22O2
MW:
258.36
Mol File:
35482-50-9.mol
More
Less

5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Chemical Properties

Boiling point:
414.3±45.0 °C(Predicted)
Density 
1.073±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
pka
9.62±0.45(Predicted)
form 
solution in acetate.
More
Less

5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Usage And Synthesis

Biological Activity

o-1821 is an cannabidiol analog with similar structure to o-1918, a selective antagonist of abnormal cannabidiol.abnormal cannabidiol, a synthetic regioisomer of cannabidiol, fails to elicit either central cannabinoid (cb1) or peripheral cannabinoid (cb2) receptors and is lack of psychotropic activity. it can induce endothelium-dependent vasodilation through a cb1/cb2/nitric oxide-independent mechanism.

in vitro

o-1821 is a cannabidiol analog with similar structure to o-1918, which was identified as a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (cb1)/peripheral cannabinoid (cb2) receptors endothelial receptor. it was found that o-1918 could not bind to cb1 or cb2 receptors and thus could not cause vasorelaxation at concentrations up to 30 μm, but it could cause concentration-dependent inhibition of the vasorelaxant effects of abn-cbd and anandamide. moreover, in human umbilical vein endothelial cells, abn-cbd was able to induce phosphorylation of p42/44 mitogenactivated protein kinase and protein kinase b/akt, which could be inhibited by o-1918 or by phosphatidylinositol 3 (pi3) kinase inhibitors [1].

in vivo

o-1918 was found to be able to inhibit the hypotensive effect of abn-cbd dose-dependently but not the hypotensive effect of the cb1 receptor agonist (-)-11-oh-δ9-tetrahydrocannabinol dimethylheptyl in anesthetized mice [1].

References

[1] offertáler, l. ,mo, f.m.,bátkai, s., et al. selective ligands and cellular effectors of a g protein-coupled endothelial cannabinoid receptor. molecular pharmacology 63(3), 699-705 (2003).

5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOLSupplier

ChemeGen(Shanghai) Biotechnology Co.,Ltd.
Tel
18818260767
Email
sales@chemegen.com
Energy Chemical
Tel
021-58432009 400-005-6266
Email
marketing@energy-chemical.com
ApexBio Technology
Tel
+ 1-832-696-8203
Email
sales@apexbt.com